| Followers | 129 |
| Posts | 2150 |
| Boards Moderated | 1 |
| Alias Born | 12/27/2007 |
Tuesday, October 08, 2019 9:56:04 AM
ASRT =FDA DECISION IN 11 DAYS....Drug targeting billion dollar market
[ASRT] Price $1.33 // Market Cap $103 // Cash $76 Million // FDA DECISION ON OCTOBER 19 = 500% Potential
Cosyntropin (Synthetic ACTH Depot) is currently not available in the U.S., but Synacten® Depot is approved and broadly used around the world for a wide array of diagnostic and therapeutic uses with broadly similar indications to Mallinckrodt’s H.P. Acthar® Gel. Presently the U.S. ACTH depot market is served by H.P. Acthar Gel which generated an estimated $1.2 billion in net sales for the twelve-month period ending June 30th, 2017. Depomed intends to seek approval for cosyntropin (Synthetic ACTH Depot) in the US and subsequent to approval Depomed and Slán will share in the net sales of cosyntropin (Synthetic ACTH Depot) for a 10-year period (after which time the product will revert back to Slán).
[ASRT] Price $1.33 // Market Cap $103 // Cash $76 Million // FDA DECISION ON OCTOBER 19 = 500% Potential
Cosyntropin (Synthetic ACTH Depot) is currently not available in the U.S., but Synacten® Depot is approved and broadly used around the world for a wide array of diagnostic and therapeutic uses with broadly similar indications to Mallinckrodt’s H.P. Acthar® Gel. Presently the U.S. ACTH depot market is served by H.P. Acthar Gel which generated an estimated $1.2 billion in net sales for the twelve-month period ending June 30th, 2017. Depomed intends to seek approval for cosyntropin (Synthetic ACTH Depot) in the US and subsequent to approval Depomed and Slán will share in the net sales of cosyntropin (Synthetic ACTH Depot) for a 10-year period (after which time the product will revert back to Slán).
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
